Galmed Pharmaceuticals (GLMD) Competitors $1.46 -0.01 (-0.34%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLMD vs. ERNA, GNPX, EPIX, PCSA, INAB, DWTX, AEON, KPRX, CELZ, and APREShould you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Ernexa Therapeutics (ERNA), Genprex (GNPX), ESSA Pharma (EPIX), Heatwurx (PCSA), IN8bio (INAB), Dogwood Therapeutics (DWTX), AEON Biopharma (AEON), Kiora Pharmaceuticals (KPRX), Creative Medical Technology (CELZ), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry. Galmed Pharmaceuticals vs. Its Competitors Ernexa Therapeutics Genprex ESSA Pharma Heatwurx IN8bio Dogwood Therapeutics AEON Biopharma Kiora Pharmaceuticals Creative Medical Technology Aprea Therapeutics Ernexa Therapeutics (NASDAQ:ERNA) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Is ERNA or GLMD more profitable? Galmed Pharmaceuticals has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Ernexa Therapeutics' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics-7,652.75% N/A -682.08% Galmed Pharmaceuticals N/A -20.69%-18.41% Which has preferable earnings and valuation, ERNA or GLMD? Galmed Pharmaceuticals has lower revenue, but higher earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErnexa Therapeutics$488K19.04-$44.54M-$8.31-0.15Galmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.09 Do insiders & institutionals hold more shares of ERNA or GLMD? 70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 4.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, ERNA or GLMD? Ernexa Therapeutics has a beta of 5.66, indicating that its stock price is 466% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Do analysts rate ERNA or GLMD? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Galmed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to ERNA or GLMD? In the previous week, Ernexa Therapeutics' average media sentiment score of 0.00 equaled Galmed Pharmaceuticals'average media sentiment score. Company Overall Sentiment Ernexa Therapeutics Neutral Galmed Pharmaceuticals Neutral SummaryGalmed Pharmaceuticals beats Ernexa Therapeutics on 7 of the 11 factors compared between the two stocks. Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLMD vs. The Competition Export to ExcelMetricGalmed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.42M$2.54B$5.72B$10.40BDividend YieldN/A53.63%5.53%4.58%P/E Ratio-0.0923.6076.4326.62Price / SalesN/A521.29472.7192.34Price / CashN/A171.0137.4661.85Price / Book0.155.3713.276.45Net Income-$7.52M$32.95M$3.29B$271.39M7 Day Performance-1.35%4.01%2.60%3.06%1 Month Performance-1.68%5.96%4.65%7.62%1 Year Performance-81.80%1.93%74.34%30.20% Galmed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLMDGalmed Pharmaceuticals0.6404 of 5 stars$1.47-0.3%N/A-84.3%$2.42MN/A-0.0920ERNAErnexa Therapeutics0.6213 of 5 stars$1.18-8.5%N/A-93.4%$9.90M$580K-0.1410High Trading VolumeGNPXGenprex0.7695 of 5 stars$0.28-5.7%N/A-47.0%$9.76MN/A0.0020Gap DownEPIXESSA Pharma2.6945 of 5 stars$0.19-5.2%$2.00+940.0%-96.8%$9.60MN/A-0.3450News CoverageDividend AnnouncementPCSAHeatwurx2.9953 of 5 stars$0.20+5.7%$1.00+399.0%-84.2%$9.55MN/A-0.0920INABIN8bio2.7035 of 5 stars$2.00-4.8%$180.00+8,900.0%-77.8%$9.53MN/A-0.2220Positive NewsDWTXDogwood Therapeutics1.3856 of 5 stars$4.93+0.8%$10.00+102.8%N/A$9.35MN/A-0.265Positive NewsAEONAEON Biopharma3.1955 of 5 stars$0.79+1.3%$360.00+45,446.6%-98.4%$9.20MN/A4.395KPRXKiora Pharmaceuticals2.4749 of 5 stars$2.61-1.1%$10.00+283.1%-29.8%$9.06M$16.02M-0.9010CELZCreative Medical Technology0.7964 of 5 stars$3.48-0.6%N/A+12.7%$9.03M$10K-1.095Positive NewsGap DownAPREAprea Therapeutics2.6611 of 5 stars$1.51-2.2%$15.50+926.5%-52.9%$8.99M$1.50M-0.657 Related Companies and Tools Related Companies ERNA Competitors GNPX Competitors EPIX Competitors PCSA Competitors INAB Competitors DWTX Competitors AEON Competitors KPRX Competitors CELZ Competitors APRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLMD) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
